SHANGHAI, China, July 14, 2026
Dizal has entered into a landmark global exclusive license agreement with AstraZeneca for Zegfrovy (sunvozertinib), a novel oral epidermal growth factor receptor (EGFR) inhibitor developed for patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. Under the terms of the agreement, AstraZeneca will receive worldwide rights to develop and commercialize Zegfrovy, significantly expanding its leadership in precision oncology and strengthening its portfolio of targeted lung cancer therapies. The transaction includes an upfront payment of $600 million, with up to $900 million in additional development, regulatory, and commercial milestone payments, alongside tiered royalties on global sales, bringing the total potential deal value to $1.5 billion before royalties. The agreement highlights the increasing global value of innovative oncology medicines discovered in China and reinforces the strategic importance of targeted therapies addressing rare EGFR mutations with significant unmet medical needs. The transaction is expected to close during the second half of 2026, subject to customary regulatory approvals and closing conditions.
Zegfrovy Strengthens AstraZeneca’s Precision Oncology Portfolio
Zegfrovy is an oral, irreversible EGFR inhibitor designed to selectively target a broad spectrum of EGFR mutations while sparing wild-type EGFR, helping improve treatment precision and tolerability. The therapy is already approved in both the United States and China for adults with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed following platinum-based chemotherapy. More recently, the investigational medicine demonstrated positive results in the global Phase III WU-KONG28 clinical trial evaluating first-line treatment for patients with EGFR exon20 insertion-positive NSCLC. These findings were presented during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine, further validating the drug’s clinical potential. Based on these results, Supplemental New Drug Applications (sNDAs) have been submitted to both the U.S. FDA and China’s Center for Drug Evaluation (CDE), while regulators in both countries have granted Breakthrough Therapy Designation for first-line use, highlighting the therapy’s potential to address a significant unmet medical need.
Global Collaboration Targets Patients with Limited Treatment Options
Lung cancer remains the leading cause of cancer-related mortality worldwide, with approximately 80–85% of all lung cancer cases classified as non-small cell lung cancer. Although EGFR mutations are common drivers of NSCLC, patients with EGFR exon 20 insertion mutations represent a particularly challenging subgroup because available targeted treatment options remain limited. Through this licensing agreement, AstraZeneca plans to leverage its established global oncology infrastructure and extensive expertise in EGFR-targeted therapies to accelerate worldwide development, regulatory expansion, and commercialization of Zegfrovy. The collaboration is expected to broaden patient access across international markets while complementing AstraZeneca’s existing portfolio of precision oncology medicines. Executives from both companies emphasized that combining Dizal’s scientific innovation with AstraZeneca’s commercial and clinical development capabilities could significantly improve treatment opportunities for patients facing aggressive forms of EGFR-mutated lung cancer.
Advertisement
Strategic Licensing Deal Highlights Growing Oncology Innovation
The agreement represents one of the most significant biopharmaceutical licensing transactions announced in 2026 and underscores the growing global recognition of innovative oncology research emerging from China’s biotechnology sector. For Dizal, the partnership provides substantial non-dilutive capital to support continued research and development across its expanding oncology and immunology pipeline, which includes multiple late-stage investigational therapies targeting difficult-to-treat cancers. For AstraZeneca, adding Zegfrovy further strengthens its position as a global leader in precision oncology, particularly within the rapidly evolving EGFR-mutated NSCLC treatment landscape. As targeted therapies continue transforming lung cancer management through personalized medicine approaches, this strategic alliance is expected to accelerate innovation, improve global patient access, and reinforce the industry’s commitment to developing next-generation treatments for patients with limited therapeutic options.
Source: Dizal, AstraZeneca press release
